ML261 CAR T Cell Therapy for Small Cell Lung Cancer

This trial tests a new treatment called ML261 (a CAR T cell therapy) for certain aggressive lung and neuroendocrine cancers. The main goal is to determine the safety of this treatment and its effectiveness in shrinking tumors. Eligible participants have previously tried other cancer treatments, experienced cancer recurrence or progression, and have a confirmed diagnosis of small cell lung cancer or specific neuroendocrine cancers. The study will also examine how the treatment moves through and affects the body. As a Phase 1 trial, this research aims to understand how the treatment works in people, offering participants the opportunity to be among the first to receive this new therapy.

The trial does not specify if you need to stop taking your current medications. However, you cannot have had recent systemic anti-cancer therapies or be on certain immunosuppressive agents before starting the trial. It's best to discuss your specific medications with the trial team.

Research has shown that ML261 CAR T cell therapy, which targets a protein called DLL3, has been safe in early studies. For example, a study with mice found no major side effects. Additionally, a similar therapy targeting DLL3 caused only mild cases of an immune response known as cytokine release syndrome in a few patients, with no deaths related to side effects. Although this trial is just beginning, these findings suggest that ML261 might be safe for humans, but further research is needed to confirm this.¹²³⁴⁵

Most treatments for small cell lung cancer, like chemotherapy and radiation, aim to kill rapidly dividing cells but often affect healthy cells too. Unlike these conventional options, ML261 uses a unique mechanism called CAR T cell therapy, specifically targeting DLL3, a protein common in cancer cells. Researchers are thrilled about ML261 because it harnesses the body's own immune system to attack cancer more precisely, potentially leading to fewer side effects and better outcomes. This precision targeting could revolutionize how effectively we treat small cell lung cancer.

Research shows that ML261 CAR T cell therapy targets a protein called DLL3, present in most small cell lung cancer (SCLC) tumors. Studies have found that targeting DLL3 holds promise because 85% to 94% of SCLC patients have this protein on their tumor cells. CAR T cells designed to attack DLL3 have demonstrated high effectiveness in lab tests on SCLC. Other similar treatments have shown early signs of combating tumors, with a response rate of 16.7%. These initial results suggest that ML261, the treatment under study in this trial, could help fight SCLC by specifically targeting and attacking cancer cells.¹⁴⁶⁷⁸